Overview

* Cogent Q2 net loss widens to $73.5 mln from nearly $59.0 mln yr ago

* Bezuclastinib shows statistically significant results in SUMMIT trial

* Co's cash position expected to fund operations through 2027, including launch

Outlook

* Company projects cash runway into 2027

Result Drivers

* R&D COSTS: R&D expenses increase mainly due to costs incurred to support on-going SUMMIT, PEAK and APEX clinical trials

* FINANCIAL POSITION - Cogent's cash position, strengthened by a recent public offering, is expected to support operations through 2027

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Net -$73.53

Income mln

Q2 -$75.58

Income mln

from

Operatio

ns

Q2 $75.58

Operatin mln

g

Expenses

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)